Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Nakamura R, et al. Among authors: katayama y. Cancer Lett. 2024 Aug 28;598:217124. doi: 10.1016/j.canlet.2024.217124. Epub 2024 Jul 24. Cancer Lett. 2024. PMID: 39059573 Free article.
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
Nishioka N, Yamada T, Harita S, Hirai S, Katayama Y, Nakano T, Okura N, Tamiya N, Kaneko Y, Uchino J, Takayama K. Nishioka N, et al. Among authors: katayama y. Respir Med Case Rep. 2018 Oct 6;25:261-263. doi: 10.1016/j.rmcr.2018.10.004. eCollection 2018. Respir Med Case Rep. 2018. PMID: 30310765 Free PMC article.
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S, Kikuchi T, Hirose K, Kubota Y, Chihara Y, Harada T, Tanimura K, Takeda T, Tamiya N, Kaneko Y, Uchino J, Takayama K. Yamada T, et al. Among authors: katayama y. Cancer Med. 2019 Apr;8(4):1521-1529. doi: 10.1002/cam4.2037. Epub 2019 Feb 21. Cancer Med. 2019. PMID: 30790471 Free PMC article.
Tumor Neovascularization and Developments in Therapeutics.
Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K. Katayama Y, et al. Cancers (Basel). 2019 Mar 6;11(3):316. doi: 10.3390/cancers11030316. Cancers (Basel). 2019. PMID: 30845711 Free PMC article. Review.
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. Okura N, et al. Among authors: katayama y. Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17. Clin Cancer Res. 2020. PMID: 31953310
2,809 results